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SYMPTOMS OF LOWER URINARY TRACT SYMPTOMS AFTER PROSTATE CANCER 
TREATMENT 
 
Hypothesis / aims of study 
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in Australian males and incidence rate have increased 
between 1982 and 2007 [1]. Lower urinary tract symptoms (LUTS) is a common complication associated prostate cancer 
treatments such as prostatectomy, radiation therapy, and brachytherapy [2] and it can have a significant effect on quality of life 
[2,3]. The aim of this cross-sectional survey was to establish the prevalence and severity of LUTS after prostate cancer 
treatment 
 
Study design, materials and methods 
This cross-sectional study was undertaken between July and December 2010 in 21 prostate cancer support groups across New 
South Wales (NSW) and Queensland (QLD), Australia. LUTS includes storage symptoms (urinary incontinence, including 
urgency, stress urinary incontinence, unconscious leaking) as well as voiding (including hesitancy, straining, slow stream, 
intermittency) and post-micturition symptoms (incomplete emptying).  
In order to investigate the prevalence of LUTS in the general community, 258 men who have had treatment for prostate cancer 
were asked to complete the ICIQ-MLUTS questionnaire (based on the ICSmaleSF). An additional questionnaire, which was 
designed for this study, asked for details of general health, prostate cancer treatment options, pelvic florr muscle training before 
treatment and demographic characteristics. Chi-square tests were used to compare the prevalence of LUTs after prostate 
cancer treatment by treatment options. 
 
Results 
All eligible men who attended support group meetings agreed to participate. Mean age was 69.9 years (Standard Deviation: 
7.89; Range 45-95 years). Of the 258 participants, 211 (82%) were not employed (either retired or unemployed) and 77 (30%) 
had a tertiary degree/diploma. The table below shows that radical prostatectomy was the predominant treatment option (68%). 
A total 245 participants (95%) reported at least one LUTS symptom. The prevalence of urinary incontinence was greater (at 
93%; n=240) than that of voiding or post micturition symptoms (38%; n=98).  About 47% of participants (n=120) carried out 
pelvic floor muscle training before undergoing treatment and were significantly less likely to report LUTS symptoms (P= 0.0424).  
 
Table 1. Prostate cancer treatments (N=258) 
 n
¥
 % 
Prostatectomy 154 67.8 
Radiation therapy 73 31.9 
Androgen Deprivation Therapy (ADT)  85 36.8 
Brachytherapy (High dose) 15 22.1 
Brachytherapy (Low dose) 10 14.3 
Watchful Waiting 5 2 
¥ 
Some participants had a combination 
 
Interpretation of results 
Despite improved treatment techniques, LUTS remains significantly prevalent after prostate cancer treatment. 
 
Concluding message 
As the risk of developing LUTS increases with increasing age and can be exacerbated by prostate cancer treatment [2], more 
research is needed in male LUTS, prostate cancer treatment and prophylactic pelvic floor muscle training. 
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